30 recruiting, 26 unknown, 20 completed, 13 active not recruiting. 109 Phase 2, 23 Phase 1, 4 Phase 3.
Follow Nab paclitaxel: new trials by email Literature Review of Nab paclitaxel trials Research Report on Nab paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC Adebrelimab, Nab paclitaxel, Carboplatin - Esophageal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2026-07-31 | 2026-07-29 |
| Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC Retlirafusp alfa, Nab paclitaxel, Cisplatin for injection - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Tang-Du Hospital | 33 | 2026-05-30 | 2026-06-01 |
| ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma ONT01, Gemcitabine, Nab paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 61 | 2026-03-25 | 2026-05-19 |
| Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer Nab paclitaxel, Carboplatin, Trastuzumab - HER2-positive Early Breast Cancer | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 200 | 2025-12-25 | 2026-01-21 |
| Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma 5-Fluorouracil, Oxaliplatin, Leucovorin - Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | University of Miami | 50 | 2025-09-09 | 2026-09-21 |
| Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer Nab paclitaxel, Gemcitabine, Cisplatin - Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation | Phase 2 / Phase 3 | Active not recruiting | University Health Network, Toronto | 10 | 2025-06-10 | 2026-06-23 |
| A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC Camrelizumab, Nab paclitaxel, Levocetirizine Hydrochloride - Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 60 | 2025-04-01 | 2025-03-26 |
| Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer Nab paclitaxel, Gemcitabine, TheraBionic P1 - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 30 | 2025-02-28 | 2026-08-10 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC bevacizumab, QL1706, Nab paclitaxel - TNBC, Triple Negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 60 | 2024-10-09 | 2025-02-06 |
| The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer Nab paclitaxel, Gemcitabine, Cisplatin - Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 10 | 2024-08-13 | 2026-10-19 |
| Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer Ivonescimab, Gemcitabine, Nab paclitaxel - Pancreatic Cancer | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 36 | 2024-07-15 | 2024-07-09 |
| LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer LM-108, Toripalimab, Eribulin - TNBC - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 74 | 2024-07-10 | 2024-08-02 |
| A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma Nab paclitaxel, Gemcitabine, NovoTTF-200T(P) - Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer | Phase 2 | Recruiting | Ashish Manne | 38 | 2024-07-01 | 2026-04-08 |
| Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial. radiotherapy, Nab paclitaxel, Cisplatin - Cervical Cancer | Phase 2 | Not yet recruiting | Peking University Third Hospital | 64 | 2024-06-01 | 2024-05-23 |
| A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. Tafolecimab, Sintilimab, Nab paclitaxel - Lung Cancer | Phase 2 | Recruiting | Jinghui Wang | 30 | 2024-05-17 | 2024-05-20 |
| Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer Camrelizumab, Cisplatin, Nab paclitaxel - Cervical Cancer, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Tongji Hospital | 40 | 2024-05-08 | 2024-11-05 |
| Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer Carboplatin, Nab paclitaxel, Sintilimab - Esophageal Cancer | Phase 2 | Unknown | Sichuan University | 68 | 2024-05-01 | 2024-05-08 |
| Newly Emerging Immunotherapy for Pancreatic Cancer Treatment JS001, JS004, JS007 - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Fudan University | 117 | 2024-04-30 | 2024-04-17 |
Showing 20 of 109. Sign in to see all of them.
Pancreatic Neoplasms (27) · Breast Neoplasms (14) · Carcinoma, Non-Small-Cell Lung (14) · Triple Negative Breast Neoplasms (10) · Neoplasm Metastasis (7) · Uterine Cervical Neoplasms (6) · Esophageal Squamous Cell Carcinoma (4) · Lung Neoplasms (4) · Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Adenocarcinoma (3) · Biliary Tract Neoplasms (3) · Esophageal Neoplasms (3) · Stomach Neoplasms (3) · Cholangiocarcinoma (2)
Fudan University (9) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (5) · Guangdong Provincial People's Hospital (4) · University of Washington (4) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Tongji Hospital (3) · BeiGene (2) · Chinese PLA General Hospital (2) · City of Hope Medical Center (2) · ImmunityBio, Inc. (2) · Qilu Pharmaceutical Co., Ltd. (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Wake Forest University Health Sciences (2) · Washington University School of Medicine (2) · AHS Cancer Control Alberta (1)
China (52) · United States (38) · Spain (8) · Australia (7) · Italy (6) · France (5) · Canada (4) · Denmark (4) · Germany (4) · South Korea (4) · Georgia (2) · Greece (2) · Moldova (2) · Taiwan (2) · United Kingdom (2)
Ding Ma (2) · Wen-zhao Zhong, PhD (2) · Zhi-Ming Shao (2) · Akito Hata (1) · Alfredo Budillon (1) · Andrew Dean (1) · Anthony F Shields, M.D. PhD (1) · Antonino Romeo, MD (1) · Antonio Avallone (1) · Ashish Manne, MD (1) · Ashwin Somasundaram, MD (1) · Barbara Goff (1)
PMID 11698646, PMID 15030777, PMID 15240681, PMID 15358536, PMID 15771580, PMID 15800326, PMID 16227604, PMID 18565862, PMID 19426218, PMID 20516428, PMID 20530281, PMID 20625120, PMID 20636820, PMID 20658263, PMID 24422706, PMID 27718847, PMID 27745820, PMID 28114604, PMID 28271869, PMID 28397821, PMID 28797458, PMID 28885881, PMID 29570421, PMID 29658848, PMID 29658856, PMID 30206369, PMID 30280635, PMID 30285770, PMID 30481287, PMID 30914290, PMID 30998813, PMID 31147146, PMID 31831564, PMID 33570247, PMID 34754076, PMID 35688554, PMID 35880942, PMID 37328835, PMID 37368098, PMID 37880682, PMID 37965307, PMID 38191175, PMID 38362377, PMID 38589856, PMID 38658024, PMID 38844468, PMID 39300376, PMID 40272619, PMID 40347227, PMID 40541191
2018 (2), P30CA012197 (2), 2016 (1), 2023 (1), K12CA226330 (1), P30CA014599 (1), P30CA015704 (1), P30CA072720 (1), P50CA272213 (1), R01CA127927 (1), R01CA138521 (1), R01CA166020 (1)